Synergistic Cancer Treatment System
Legal Citation
Summary of the Inventive Concept
A comprehensive system integrating anti-MICA antigen binding fragments with AI, IoT, blockchain, and new materials to revolutionize cancer treatment
Background and Problem Solved
The original patent disclosed anti-MICA antigen binding fragments for cancer treatment. However, it lacked a comprehensive system to optimize treatment regimens, ensure secure tracking, and provide personalized therapy. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system
Detailed Description of the Inventive Concept
The synergistic system comprises a bi-specific T-cell engager, an artificial intelligence module for optimizing treatment regimens, a blockchain-based system for secure tracking, a composite material for cancer immunotherapy, and an IoT device for monitoring efficacy. The bi-specific T-cell engager is a fusion protein with two different single-chain variable fragments (scFvs), one binding to MICA or MICB and the other to an immune cell target. The AI module analyzes patient genomic data to identify specific MICA or MICB epitopes associated with the patient's cancer. The blockchain-based system ensures compliance with regulatory requirements, while the composite material provides a biodegradable polymer matrix for dispersing the bi-specific T-cell engager. The IoT device monitors the efficacy of the bi-specific T-cell engager, detecting the presence of MICA or MICB on cancer cells
Novelty and Inventive Step
The new claims introduce a synergistic combination of anti-MICA antigen binding fragments with AI, IoT, blockchain, and new materials, which is not obvious from the original patent. The integration of these distinct technologies creates a more powerful system that provides a novel approach to cancer treatment
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, blockchain platforms, or composite materials. Variations may also include integrating additional technologies, such as CRISPR gene editing, to further enhance the system's capabilities
Potential Commercial Applications and Market
The synergistic cancer treatment system has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in personalized cancer treatment, cancer immunotherapy, and precision medicine
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology, immunotherapy, and molecular biology, with expertise in chimeric antigen receptors (CARs), antibody engineering, and cancer treatment technologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with a PhD in biotechnology or molecular biology, experienced in antibody design, cancer immunotherapy, and protein engineering techniques, familiar with emerging technologies like AI and IoT in medical applications
Obviousness Rationale
A person of ordinary skill would recognize that combining the source patent's anti-MICA antibody fragment technology with emerging digital and material technologies represents a predictable extension of existing cancer immunotherapy approaches. The fundamental molecular engineering principles underlying the anti-MICA CAR are readily adaptable to more complex systemic treatment strategies. The integration of AI, blockchain, and IoT represents a natural progression of personalized medicine technologies that a skilled practitioner would find obvious given the state of biotechnology and digital health innovations.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,571 |
|---|---|
| Title | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| Assignee(s) | The Trustees of Dartmouth College |